What is the patent associated with leniolisib?
Patent US8653092 covers leniolisib, a drug developed for the treatment of activated PI3K-delta syndrome (APDS) [1]. The patent was filed on October 7, 2011, and issued on May 6, 2014 [1]. DrugPatentWatch.com tracks patent information for drugs like leniolisib [2].
When does the patent for leniolisib expire?
The expiration date for patent US8653092, associated with leniolisib, is May 6, 2031 [1].
What is leniolisib used for?
Leniolisib is a phosphoinositide 3-kinase (PI3K) delta inhibitor used to treat activated PI3K-delta syndrome (APDS) [1]. APDS is a rare primary immunodeficiency disease that can cause recurrent sinopulmonary infections, autoimmune cytopenias, and other complications [3].
How does leniolisib work?
Leniolisib works by inhibiting the delta isoform of phosphoinositide 3-kinase (PI3Kδ) [1]. This pathway plays a crucial role in the development and function of immune cells, and its dysregulation is a hallmark of APDS [3]. By blocking PI3Kδ, leniolisib aims to restore normal immune cell function [3].
Who developed leniolisib?
Leniolisib was developed by BioCryst Pharmaceuticals [3].
What are the potential risks or side effects of leniolisib?
Common side effects of leniolisib include upper respiratory tract infections, headache, and rash [3].
What is the regulatory status of leniolisib?
Leniolisib has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the treatment of APDS [3].
---
Sources:
[1] United States Patent US8653092B2. (2014, May 6). https://patents.google.com/patent/US8653092B2/en
[2] DrugPatentWatch.com. (n.d.). https://www.drugpatentwatch.com/
[3] BioCryst Pharmaceuticals. (n.d.). Leniolisib. https://www.biocryst.com/our-science/pipeline/leniolisib/